Clinical Trials Data Monitoring Committees
"Clinical Trials Data Monitoring Committees" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Committees established to review interim data and efficacy outcomes in clinical trials. The findings of these committees are used in deciding whether a trial should be continued as designed, changed, or terminated. Government regulations regarding federally-funded research involving human subjects (the "Common Rule") require (45 CFR 46.111) that research ethics committees reviewing large-scale clinical trials monitor the data collected using a mechanism such as a data monitoring committee. FDA regulations (21 CFR 50.24) require that such committees be established to monitor studies conducted in emergency settings.
Descriptor ID |
D026661
|
MeSH Number(s) |
N05.700.685.149
|
Concept/Terms |
Clinical Trials Data Monitoring Committees- Clinical Trials Data Monitoring Committees
- Data Monitoring Committees
- Committee, Data Monitoring
- Committees, Data Monitoring
- Data Monitoring Committee
- Monitoring Committee, Data
- Monitoring Committees, Data
- Safety Monitoring Boards
- Board, Safety Monitoring
- Boards, Safety Monitoring
- Monitoring Board, Safety
- Monitoring Boards, Safety
- Safety Monitoring Board
- Data and Safety Monitoring Boards
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials Data Monitoring Committees".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials Data Monitoring Committees".
This graph shows the total number of publications written about "Clinical Trials Data Monitoring Committees" by people in this website by year, and whether "Clinical Trials Data Monitoring Committees" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 0 | 1 | 1 |
2006 | 1 | 1 | 2 |
2007 | 0 | 1 | 1 |
2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Clinical Trials Data Monitoring Committees" by people in Profiles.
-
Hanscom BS, Donnell DJ, Fleming TR, Hughes JP, McCauley M, Grinsztejn B, Landovitz RJ, Emerson SS. Evaluating group-sequential non-inferiority clinical trials following interim stopping: The HIV Prevention Trials Network 083 trial. Clin Trials. 2022 12; 19(6):605-612.
-
Hedlin H, Garcia A, Weng Y, He Z, Sundaram V, Bunning B, Balasubramanian V, Cunanan K, Kapphahn K, Gummidipundi S, Purington N, Boulos M, Desai M. Clinical trials in a COVID-19 pandemic: Shared infrastructure for continuous learning in a rapidly changing landscape. Clin Trials. 2021 06; 18(3):324-334.
-
Melidis C, Bosch WR, Izewska J, Fidarova E, Zubizarreta E, Ulin K, Ishikura S, Followill D, Galvin J, Haworth A, Besuijen D, Clark CH, Clark CH, Miles E, Aird E, Weber DC, Hurkmans CW, Verellen D. Global harmonization of quality assurance naming conventions in radiation therapy clinical trials. Int J Radiat Oncol Biol Phys. 2014 Dec 01; 90(5):1242-9.
-
Yu J, Straube W, Mayo C, Giaddui T, Bosch W, Ulin K, Kry SF, Galvin J, Xiao Y. Radiation therapy digital data submission process for national clinical trials network. Int J Radiat Oncol Biol Phys. 2014 Oct 01; 90(2):466-7.
-
Irwin RS. Clinical trial registration promotes patient protection and benefit, advances the trust of everyone, and is required. Chest. 2007 Mar; 131(3):639-41.
-
Flotte TR, Frentzen B, Humphries MR, Rosenbloom AL. Recent developments in the protection of pediatric research subjects. J Pediatr. 2006 Sep; 149(3):285-286.
-
Mills E, Cooper C, Wu P, Rachlis B, Singh S, Guyatt GH. Randomized trials stopped early for harm in HIV/AIDS: a systematic survey. HIV Clin Trials. 2006 Jan-Feb; 7(1):24-33.
-
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002 Jul 17; 288(3):321-33.